Latest News

March 19, 2010 – Last week, in partnership with the Coalition for Pulmonary Fibrosis, the Pulmonary Fibrosis Foundation submitted the following editorial response to a recent New York Times feature story announcing a financial settlement for first responders to the attacks on the World Trade Centers on 9/11/01.

Though the news last week was good news for the 10,000 brave first responders

By Suzette Parmley

Biotech firm Promedior Inc. of Malvern announced a $12 million Series C financing today, bringing its total capital raised in the last year to $27 million.

The clinical stage biotechnology company said proceeds from the financing will help accelerate development of its lead drug candidate - PRM-151 - to treat inflammatory and fibrotic diseases in Phase 2 clinical trials.

March 13, 2010 - The Coalition for Pulmonary Fibrosis (CPF) and the Pulmonary Fibrosis Foundation (PFF) are applauding the efforts of Pulmonary Fibrosis (PF) patients and family members for their work to convey to the FDA and an FDA Advisory Committee the sense of urgency and desperation regarding the disease and the lack of treatment options.

POSTED: Friday, March 12, 2010 --- 9:35 p.m.

This is one of Your Stories.

A local woman e-mailed us suggesting we do our part to make everyone aware of the dangers of a common but relatively unknown disease.

She's hoping her personal tragedy will help others.

Every year this lung disease kills as many people as breast cancer but Ginger Spaight is just one of many who had no idea what P

By MATTHEW PERRONE -AP Business Writer

Federal health advisers on Tuesday voted in favor of an experimental drug from InterMune Inc., despite mixed evidence of whether it provides significant benefits for patients with a rare lung disease.

The Food and Drug Administration's panel of lung experts voted 9-3 to recommend approval of the company's drug pirfenidone.

Company to Continue Developmental Work on IPF in Conjunction With the University of Rochester

March 04, 2010: ImmuneRegen BioSciences Inc announced the submission of an application for Orphan Drug Product Designation for the company's lead compound, Homspera®, for the application of treating IPF.

March 2, 2010 - InterMune, Inc. has announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval to market pirfenidone for the treatment of patients with IPF in the European Union (EU). Currently, there are no EMA-approved treatments for IPF in the EU.

March 1, 2010 – Actelion, Ltd today announced the initial results of BUILD-3, a clinical study evaluating the safety and efficacy of bosentan in patients suffering from idiopathic pulmonary fibrosis (IPF). While there was a consistent trend in favor of bosentan, the primary endpoint, reduction in morbidity/mortality, was not met.